Abstract
Type B gelatin-based engineered nanocarrier systems (GENS) have been used over the last several years as a non-condensing systemic and oral DNA delivery system. In this study, we have modified the surface of GENS with epidermal growth factor receptor (EGFR)-targeting peptide for gene delivery and transfection in pancreatic cancer cell lines. GENS were prepared by the solvent displacement method and the EGFR-targeting peptide was grafted on the surface using a hetero-bifunctional poly(ethylene glycol) (PEG) spacer. Plasmid DNA, encoding for enhanced green fluorescent protein (GFP), was efficiently encapsulated and protected from degrading enzymes in the control and surface-modified GENS. Upon incubation with EGFR over-expressing Panc-1 human pancreatic adenocarcinoma cells, the peptide-modified nanoparticles were found to be internalized efficiently by receptor-mediated endocytosis. Both quantitative and qualitative transgene expression efficiencies were significantly enhanced when plasmid DNA was administered with EGFR-targeted GENS relative to the control-unmodified gelatin or PEG-modified gelatin nanoparticle systems. Based on these preliminary results, EGFR-targeted GENS show tremendous promise as a safe and effective gene delivery vector with the potential to treat pancreatic cancer.
Similar content being viewed by others
References
A. Jemal, R. C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E. J. Feuer, and M. J. Thun. Cancer statistics, 2004. CA Cancer J. Clin. 54:8–29 (2004).
B. E. Huber. Gene therapy strategies for treating neoplastic disease. Ann. N. Y. Acad. Sci. 716:6–11 (1994). discussion 20–12.
J. A. Roth. Adenovirus p53 gene therapy. Expert. Opin. Biol. Ther. 6:55–61 (2006).
J. A. Roth. Gene replacement strategies for lung cancer. Curr. Opin. Oncol. 10:127–132 (1998).
J. A. Roth. Gene replacement strategies for cancer. Isr. J. Med. Sci. 32:89–94 (1996).
J. A. Roth, and S. F. Grammer. Gene replacement therapy for non-small cell lung cancer: a review. Hematol. Oncol. Clin. North Am. 18:215–229 (2004).
J. A. Roth, and S. F. Grammer. Tumor suppressor gene therapy. Methods Mol. Biol. 223:577–598 (2003).
J. A. Roth, S. F. Grammer, S. G. Swisher, R. Komaki, J. Nemunaitis, J. Merritt, and R. E. Meyn. P53 gene replacement for cancer-interactions with DNA damaging agents. Acta. Oncol. 40:739–744 (2001).
J. A. Roth, S. G. Swisher, and R. E. Meyn. p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park). 13:148–154 (1999).
P. D. Wadhwa, S. P. Zielske, J. C. Roth, C. B. Ballas, J. E. Bowman, and S. L. Gerson. Cancer gene therapy: scientific basis. Annu. Rev. Med. 53:437–452 (2002).
D. Jacob, J. J. Davis, L. Zhang, H. Zhu, F. Teraishi, and B. Fang. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther. 12(2):109–115 (2005).
A. S. Pearson, M. Bouvet, D. B. Evans, and J. A. Roth. Gene therapy and pancreatic cancer. Front Biosci. 3:E230–237 (1998).
T. Blessing, J. S. Remy, and J. P. Behr. Monomolecular collapse of plasmid DNA into stable virus-like particles. Proc. Natl. Acad. Sci. U. S. A. 95(4):1427–1431 (1998).
E. Marshall. Gene therapy on trial. Science. 288:951–957 (2000).
E. Check. Gene therapy: shining hopes dented—but not dashed. Nature. 420:735 (2002).
C. E. Thomas, A. Ehrhardt, and M. A. Kay. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5):346–358 (2003).
H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release. 114(1):100–109 (2006).
J. Panyam, and V. Labhasetwar. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55:329–347 (2003).
M. Dellian, F. Yuan, V. S. Trubetskoy, V. P. Torchilin, and R. K. Jain. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer. 82(9):1513–1518 (2000).
M. D. Bhavsar, and M. M. Amiji. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech. 9:288–294 (2008).
M. D. Bhavsar, and M. M. Amiji. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene. Ther. 15(17):1200–1209 (2008).
M. D. Bhavsar, and M. M. Amiji. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release. 119:339–348 (2007).
M. D. Bhavsar, S. B. Tiwari, and M. M. Amiji. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release. 110:422–430 (2006).
G. Kaul, and M. Amiji. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J. Drug Target. 12:585–591 (2004).
G. Kaul, and M. Amiji. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm. Res. 22:951–961 (2005).
S. Kommareddy, and M. Amiji. Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine. 3:32–42 (2007).
S. Kommareddy, and M. Amiji. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J. Pharm. Sci. 96:397–407 (2007).
S. Kommareddy, and M. Amiji. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug. Chem. 16:1423–1432 (2005).
S. Kommareddy, and M. Amiji. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 14:488–498 (2007).
C. Neves, V. Escriou, G. Byk, D. Scherman, and P. Wils. Intracellular fate and nuclear targeting of plasmid DNA. Cell Boil. Toxicol. 15:193–202 (1999).
K. Tobita, H. Kijima, S. Dowaki, H. Kashiwagi, Y. Ohtani, Y. Oida, H. Yamazaki, M. Nakamura, Y. Ueyama, M. Tanaka, S. Inokuchi, and H. Makuuchi. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int. J. Mol. Med. 11:305–309 (2003).
Y. Yamanaka, H. Friess, M. S. Kobrin, M. Buchler, H. G. Beger, and M. Korc. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 13:565–569 (1993).
T. A. Jarvinen, and E. Ruoslahti. Molecular changes in the vasculature of injured tissues. Am. J. Pathol. 171:702–711 (2007).
Z. Li, R. Zhao, X. Wu, Y. Sun, M. Yao, J. Li, Y. Xu, and J. Gu. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19:1978–1985 (2005).
S. Zitzmann, V. Ehemann, and M. Schwab. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 62:5139–5143 (2002).
V. Guillemard, H. Nedev, A. Berezov, R. Murali, and H. U. Saragovi. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol. 24(6):351–358 (2005).
P. Chan, H. P. Nestler, and W. T. Miller. Investigating the substrate specificity of the HER2/Neu tyrosine kinase using peptide libraries. Cancer Lett. 160(2):159–169 (2000).
Acknowledgments
Padmaja Magadala is a Fellow in the Nanomedicine Science and Technology Interdisciplinary Graduate Education and Research Training (IGERT) program. This pre-doctoral program is supported by the National Cancer Institute (NCI) and the National Science Foundation (NSF). Scanning electron microscopy was performed at Northeastern University’s Electron Microscopy Center. We deeply appreciate the assistance of Mr. Luis Brito with the flow cytometry analysis. Flow cytometry studies were performed in Professor Vladimir Torchilin’s Lab at Northeastern University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Magadala, P., Amiji, M. Epidermal Growth Factor Receptor-Targeted Gelatin-Based Engineered Nanocarriers for DNA Delivery and Transfection in Human Pancreatic Cancer Cells. AAPS J 10, 565–576 (2008). https://doi.org/10.1208/s12248-008-9065-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-008-9065-0